EPO in very preterm infants does not improve neurodevelopmental outcomes at 2 years
Tuesday, May 17, 2016 - 13:20
in Health & Medicine
A new study randomly assigned 448 preterm infants born between 26 weeks 0 days' and 31 weeks 6 days' gestation to receive either high-dose recombinant human erythropoietin (rhEPO) or placebo (saline) intravenously within 3 hours, at 12 to 18 hours, and at 36 to 42 hours after birth.